NewsRoom Articles - Page 1350 of 1435

WednesdayFeb 15, 2017 2:15 pm

OncoCyte Corporation (NYSE: OCX) Starts Presentation at 2017 Disruptive Growth & Healthcare Conference

OncoCyte (NYSE: OCX) focuses on the development and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using proprietary sets of genetic and protein markers expressed in various types of cancers. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. For more information, visit the company’s website at www.oncocyte.com. About NetworkNewsWire NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial…

WednesdayFeb 15, 2017 1:54 pm

SeeThruEquity Report Highlights Recent ChineseInvestors.com, Inc. (CIIX) Investments

A SeeThruEquity report released in February revealed that ChineseInvestors.com, Inc. (OTCQB: CIIX), a specialized investment services company targeting primarily the Chinese-speaking population in the U.S., has made several investments in the global cannabis industry, increasing its growth potential. Still in the early stages of market penetration, the company cited significant potential in its legal cannabis initiatives. Catalysts for potential future growth include a current stake in Medicine Man Technologies, Inc. (OTCQB: MDCL), a business with cultivation, production, and dispensary operations, which has already generated proceeds from stock sales. The company’s recent achievements include completing a $5 million private placement of…

WednesdayFeb 15, 2017 1:45 pm

22nd Century (NYSE: XXII) Starts Presentation at 2017 Disruptive Growth & Healthcare Conference

22nd Century (NYSE: XXII) is a plant biotech company providing technology that allows for the level of nicotine and other nicotinic alkaloids in tobacco plants and the level of cannabinoids in cannabis plants to be decreased or increased through genetic engineering and plant breeding. The company develops smoking cessation products and modified risk tobacco products for smokers who are unable or unwilling to quit smoking and who may be interested in cigarettes, which reduce exposure to nicotine or to certain tobacco smoke toxins and/or pose a lower health risk than conventional cigarettes. For more information, visit the company's website at…

WednesdayFeb 15, 2017 1:15 pm

BioTime (NYSE: BTX) Starts Presentation at 2017 Disruptive Growth & Healthcare Conference

BioTime (NYSE: BTX) is a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases. The foundation of BioTime's core therapeutic technology platform is pluripotent cells, which are capable of becoming any of the cell types in the human body. Pluripotent cells have potential application in many areas of medicine with large unmet patient needs, including various age-related degenerative diseases and degenerative conditions for which there presently are no cures. Unlike pharmaceuticals that require a molecular target, therapeutic strategies based on the use of pluripotent cells are generally aimed at regenerating or replacing affected cells and tissues, and…

WednesdayFeb 15, 2017 1:15 pm

MagneGas Corp. (NASDAQ: MNGA) Starts Presentation at 2017 Disruptive Growth & Healthcare Conference

MagneGas (NASDAQ: MNGA) is an alternative energy company that creates and produces hydrogen-based alternative fuel through the gasification of carbon-rich liquids in the United States and internationally. The company produces gas bottled in cylinders and distributes to the metalworking market as an alternative to acetylene. It offers MagneGas, a fuel that primarily comprises hydrogen; and Plasma Arc Flow refineries that produce gas. The company also sells and licenses the plasma arc technology for the processing of liquid waste. For more information, visit the company’s website at www.magnegas.com. About NetworkNewsWire NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services…

WednesdayFeb 15, 2017 12:45 pm

Inventergy Global, Inc. (NASDAQ: INVT) Starts Presentation at 2017 Disruptive Growth & Healthcare Conference

Inventergy Global (NASDAQ: INVT) operates as an intellectual property (IP) investment and licensing company. It offers corporate licensing model for IP value creation that provides short term returns and long-term licensing revenue. Inventergy acquires portfolios in the telecommunications’ industry, primarily in core network infrastructure and mobile broadband communications segments. It is dedicated to identifying, acquiring and licensing patented technologies of market-significant technology leaders and small companies. For more information, visit the company’s website at www.inventergy.com. About NetworkNewsWire NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial…

WednesdayFeb 15, 2017 12:45 pm

IsoRay (NYSE: ISR) Starts Presentation at 2017 Disruptive Growth & Healthcare Conference

IsoRay (NYSE: ISR) develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma. It sells its products to facilities or physician practices that utilize multiple surgical facilities at which primarily prostate brachytherapy procedures are performed. For more information, visit the company's website at www.isoray.com. About NetworkNewsWire NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array…

WednesdayFeb 15, 2017 11:45 am

Lightbridge (NASDAQ: LTBR) Starts Presentation at 2017 Disruptive Growth & Healthcare Conference

Lightbridge (NASDAQ: LTBR) is a nuclear fuel technology company that operates in two segments: technology and consulting. The company offers all-metal fuel for operating and new build reactors; all-uranium seed and blanket fuel for existing plants and new build reactors; and thorium-based seed and blanket fuel for existing and new build reactors. The company's services include integrated strategic advice across a range of areas, including regulatory development, nuclear reactor site selection, procurement and deployment, reactor and fuel technology, international relations, program management, regulatory affairs, and infrastructure development. For more information, visit the company website at www.ltbridge.com. About NetworkNewsWire NetworkNewsWire (NNW)…

WednesdayFeb 15, 2017 11:45 am

Safeguard Scientifics (NYSE: SFE) Starts Presentation at 2017 Disruptive Growth & Healthcare Conference

Safeguard Scientifics (NYSE: SFE) provides capital and relevant expertise to fuel the growth of technology-driven businesses in healthcare, financial services and digital media. The company targets companies that are capitalizing on the next wave of enabling technologies with a particular focus on the Internet of Everything, enhanced security and predictive analytics. Safeguard typically deploys between $5 million and $25 million over the course of its partnership with a company, initially investing in a Series A or B Round and opportunistically in a Seed Round. Safeguard has a distinguished track record of fostering innovation and building market leaders that spans more…

WednesdayFeb 15, 2017 11:45 am

Immune Pharmaceuticals, Inc. (NASDQ: IMNP) Starts Presentation at 2017 Disruptive Growth & Healthcare Conference

Immune Pharmaceuticals (NASDAQ: IMNP) is focused on developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. The company’s lead product candidate, bertilimumab, is in phase II clinical development for moderate-to-severe ulcerative colitis as well as for bullous pemphigoid, an orphan autoimmune dermatological condition. Other indications being considered for development include atopic dermatitis, Crohn's disease, severe asthma and Non-Alcoholic Steato-Hepatitis (NASH), an inflammatory liver disease. Immune’s portfolio in immuno-dermatology includes a treatment for psoriasis and atopic dermatitis. Its oncology pipeline includes Ceplene® for maintenance remission in Acute Myeloid Leukemia (AML) in combination with…

Financial news and publishing for public and private companies

Contact us: 512.354.7000

OncoCyte Corporation (NYSE: OCX) Starts Presentation at 2017 Disruptive Growth & Healthcare Conference

SeeThruEquity Report Highlights Recent ChineseInvestors.com, Inc. (CIIX) Investments

22nd Century (NYSE: XXII) Starts Presentation at 2017 Disruptive Growth & Healthcare Conference

BioTime (NYSE: BTX) Starts Presentation at 2017 Disruptive Growth & Healthcare Conference

MagneGas Corp. (NASDAQ: MNGA) Starts Presentation at 2017 Disruptive Growth & Healthcare Conference

Inventergy Global, Inc. (NASDAQ: INVT) Starts Presentation at 2017 Disruptive Growth & Healthcare Conference

IsoRay (NYSE: ISR) Starts Presentation at 2017 Disruptive Growth & Healthcare Conference

Lightbridge (NASDAQ: LTBR) Starts Presentation at 2017 Disruptive Growth & Healthcare Conference

Safeguard Scientifics (NYSE: SFE) Starts Presentation at 2017 Disruptive Growth & Healthcare Conference

Immune Pharmaceuticals, Inc. (NASDQ: IMNP) Starts Presentation at 2017 Disruptive Growth & Healthcare Conference

NetworkNewsWire Currently Accepts

NetworkNewsWire

Financial news and publishing for public and private companies

Contact us: 512.354.7000

NetworkNewsWire Currently Accepts

Company Search

Site Search